BPMC - Blueprint Medicines dips despite Q2 beat
2023-08-02 14:56:50 ET
More on Blueprint Medicines
- Blueprint Medicines Corporation 2023 Q2 - Results - Earnings Call Presentation
- Blueprint Medicines Corporation ( BPMC ) Q2 2023 Earnings Call Transcript
- Blueprint Is Well-Positioned To Capitalize On ISM Market (Maintain 'Buy')
- Blueprint granted FDA label expansion for Ayvakit
- Seeking Alpha’s Quant Rating on Blueprint Medicines
For further details see:
Blueprint Medicines dips despite Q2 beat